Ken Griffin Monte Rosa Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Put Options

5 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$3.59 - $6.97 $81,493 - $158,219
22,700 Added 267.06%
31,200 $165,000
Q2 2024

Aug 14, 2024
BUY
$3.38 - $7.86 $24,674 - $57,378
7,300 Added 608.33%
8,500 $31,000
Q1 2024

May 15, 2024
SELL
$4.26 - $8.46 $41,748 - $82,908
-9,800 Reduced 89.09%
1,200 $8,000
Q4 2023

Feb 14, 2024
BUY
$2.5 - $5.93 $27,500 - $65,230
11,000 New
11,000 $62,000
Q4 2022

Feb 14, 2023
BUY
$6.71 - $9.72 $9,394 - $13,608
1,400 New
1,400 $10,000

Others Institutions Holding GLUE

# of Institutions
83
Shares Held
43.9M
Call Options Held
141K
Put Options Held
31.2K
View Full List

About Monte Rosa Therapeutics, Inc.

GLUE Quotes by TradingView
  • Ticker GLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,713,900
  • Market Cap $329M
  • Description
  • Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...
More about GLUE
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email